Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia | 9 | 2022 | 183 | 3.710 |
Why?
|
| Community-Acquired Infections | 9 | 2022 | 65 | 2.690 |
Why?
|
| Patient Discharge | 6 | 2023 | 326 | 2.070 |
Why?
|
| Hospitalization | 8 | 2023 | 888 | 1.810 |
Why?
|
| Hospital Medicine | 2 | 2023 | 23 | 1.630 |
Why?
|
| Physicians | 7 | 2021 | 692 | 1.440 |
Why?
|
| Sepsis | 3 | 2024 | 329 | 1.360 |
Why?
|
| Length of Stay | 8 | 2023 | 749 | 1.300 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 1862 | 1.220 |
Why?
|
| Patient Readmission | 7 | 2023 | 355 | 1.160 |
Why?
|
| Neuroblastoma | 6 | 2017 | 400 | 1.120 |
Why?
|
| Patient Satisfaction | 4 | 2020 | 460 | 1.120 |
Why?
|
| Clinical Coding | 3 | 2024 | 24 | 1.100 |
Why?
|
| Decision Making | 7 | 2021 | 671 | 1.080 |
Why?
|
| Hospital Mortality | 4 | 2022 | 408 | 1.060 |
Why?
|
| Internship and Residency | 4 | 2022 | 1063 | 0.910 |
Why?
|
| Copyright | 2 | 2013 | 2 | 0.880 |
Why?
|
| Publishing | 1 | 2024 | 90 | 0.870 |
Why?
|
| Medical Overuse | 2 | 2021 | 36 | 0.860 |
Why?
|
| Skilled Nursing Facilities | 1 | 2023 | 43 | 0.860 |
Why?
|
| Cross Infection | 2 | 2021 | 151 | 0.830 |
Why?
|
| Physician-Patient Relations | 5 | 2021 | 625 | 0.820 |
Why?
|
| Humans | 57 | 2024 | 89985 | 0.800 |
Why?
|
| Respiratory Insufficiency | 2 | 2022 | 162 | 0.770 |
Why?
|
| Comorbidity | 4 | 2018 | 953 | 0.750 |
Why?
|
| Medicare | 4 | 2022 | 427 | 0.750 |
Why?
|
| Universal Precautions | 1 | 2021 | 5 | 0.740 |
Why?
|
| Mental Fatigue | 1 | 2021 | 9 | 0.740 |
Why?
|
| United States | 18 | 2022 | 7114 | 0.710 |
Why?
|
| Personal Autonomy | 1 | 2021 | 115 | 0.700 |
Why?
|
| Patient Preference | 2 | 2020 | 112 | 0.690 |
Why?
|
| Hospitalists | 1 | 2021 | 139 | 0.660 |
Why?
|
| Education, Medical, Graduate | 2 | 2013 | 403 | 0.650 |
Why?
|
| Occupational Exposure | 1 | 2020 | 87 | 0.650 |
Why?
|
| Marital Status | 1 | 2019 | 42 | 0.640 |
Why?
|
| Patient Participation | 2 | 2020 | 226 | 0.630 |
Why?
|
| Health Personnel | 1 | 2021 | 214 | 0.630 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 437 | 0.630 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2018 | 19 | 0.620 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2018 | 35 | 0.620 |
Why?
|
| Splenic Diseases | 1 | 2018 | 15 | 0.620 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.610 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 305 | 0.610 |
Why?
|
| Pancreatitis | 1 | 2018 | 86 | 0.590 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2017 | 239 | 0.570 |
Why?
|
| Data Collection | 1 | 2018 | 377 | 0.560 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 69 | 0.550 |
Why?
|
| Colonic Diseases | 1 | 2017 | 61 | 0.550 |
Why?
|
| Gastroenterologists | 1 | 2017 | 31 | 0.550 |
Why?
|
| Mass Screening | 1 | 2021 | 647 | 0.530 |
Why?
|
| Ambulatory Care | 2 | 2016 | 186 | 0.530 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 262 | 0.530 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 250 | 0.520 |
Why?
|
| Communication | 2 | 2016 | 461 | 0.510 |
Why?
|
| Periodicals as Topic | 2 | 2024 | 168 | 0.500 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 437 | 0.490 |
Why?
|
| Patient-Centered Care | 4 | 2021 | 210 | 0.490 |
Why?
|
| Colonoscopy | 1 | 2017 | 281 | 0.490 |
Why?
|
| Pandemics | 2 | 2020 | 778 | 0.480 |
Why?
|
| Terminal Care | 1 | 2016 | 137 | 0.480 |
Why?
|
| Logistic Models | 6 | 2019 | 1214 | 0.470 |
Why?
|
| Hospital-Physician Joint Ventures | 1 | 2014 | 3 | 0.470 |
Why?
|
| Constipation | 1 | 2015 | 64 | 0.470 |
Why?
|
| Comprehensive Health Care | 1 | 2014 | 13 | 0.460 |
Why?
|
| Palliative Care | 1 | 2016 | 264 | 0.460 |
Why?
|
| Office Visits | 1 | 2014 | 50 | 0.450 |
Why?
|
| Waiting Lists | 2 | 2015 | 187 | 0.450 |
Why?
|
| Health Status Indicators | 1 | 2014 | 103 | 0.440 |
Why?
|
| Hospital Costs | 1 | 2014 | 109 | 0.430 |
Why?
|
| Critical Care | 1 | 2016 | 384 | 0.430 |
Why?
|
| Male | 24 | 2020 | 42690 | 0.420 |
Why?
|
| Inpatients | 4 | 2022 | 312 | 0.420 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 596 | 0.410 |
Why?
|
| Aged | 17 | 2020 | 19262 | 0.400 |
Why?
|
| Holidays | 1 | 2011 | 4 | 0.400 |
Why?
|
| Wit and Humor as Topic | 1 | 2011 | 13 | 0.400 |
Why?
|
| Intensive Care Units | 1 | 2015 | 398 | 0.400 |
Why?
|
| Hospitals, General | 1 | 2011 | 12 | 0.390 |
Why?
|
| Famous Persons | 1 | 2011 | 8 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 608 | 0.390 |
Why?
|
| Teaching Rounds | 1 | 2011 | 25 | 0.380 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 6785 | 0.380 |
Why?
|
| Middle Aged | 18 | 2020 | 26159 | 0.370 |
Why?
|
| Personal Protective Equipment | 2 | 2021 | 35 | 0.370 |
Why?
|
| Art | 1 | 2010 | 5 | 0.360 |
Why?
|
| Search Engine | 1 | 2010 | 10 | 0.360 |
Why?
|
| Female | 22 | 2020 | 46602 | 0.350 |
Why?
|
| Risk Factors | 9 | 2018 | 5562 | 0.350 |
Why?
|
| Infection Control | 2 | 2021 | 124 | 0.330 |
Why?
|
| Adult | 17 | 2022 | 26827 | 0.320 |
Why?
|
| Sex Factors | 4 | 2018 | 1075 | 0.320 |
Why?
|
| Terminology as Topic | 1 | 2010 | 222 | 0.320 |
Why?
|
| Age Factors | 4 | 2018 | 1880 | 0.310 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 384 | 0.300 |
Why?
|
| Internet | 1 | 2010 | 323 | 0.300 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2017 | 18 | 0.280 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 45 | 0.280 |
Why?
|
| Palmitic Acid | 1 | 2016 | 27 | 0.270 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.270 |
Why?
|
| Acute Disease | 2 | 2021 | 846 | 0.270 |
Why?
|
| Chicago | 4 | 2020 | 1434 | 0.270 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2017 | 128 | 0.260 |
Why?
|
| Antithrombin III Deficiency | 1 | 2005 | 3 | 0.260 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 529 | 0.260 |
Why?
|
| Trisomy | 1 | 2005 | 54 | 0.260 |
Why?
|
| Behcet Syndrome | 1 | 2005 | 15 | 0.250 |
Why?
|
| Mosaicism | 1 | 2005 | 71 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2005 | 83 | 0.250 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 201 | 0.250 |
Why?
|
| Odds Ratio | 3 | 2019 | 682 | 0.250 |
Why?
|
| Genes, myc | 1 | 2015 | 40 | 0.250 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 338 | 0.240 |
Why?
|
| Intestinal Diseases | 1 | 2005 | 79 | 0.240 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 63 | 0.240 |
Why?
|
| Obesity | 1 | 2011 | 972 | 0.240 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 321 | 0.230 |
Why?
|
| Writing | 1 | 2024 | 29 | 0.230 |
Why?
|
| Risk Assessment | 3 | 2018 | 2327 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2005 | 360 | 0.200 |
Why?
|
| Informed Consent | 2 | 2021 | 275 | 0.190 |
Why?
|
| Occupations | 1 | 2021 | 25 | 0.190 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 54 | 0.190 |
Why?
|
| Goals | 1 | 2021 | 67 | 0.190 |
Why?
|
| Treatment Refusal | 1 | 2021 | 62 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 32 | 0.180 |
Why?
|
| Euthanasia, Passive | 1 | 2000 | 16 | 0.180 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 728 | 0.180 |
Why?
|
| Patient Advocacy | 1 | 2000 | 53 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 665 | 0.180 |
Why?
|
| Suicide, Assisted | 1 | 2000 | 33 | 0.180 |
Why?
|
| Betacoronavirus | 2 | 2020 | 262 | 0.180 |
Why?
|
| Risk Management | 1 | 2020 | 44 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 76 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2014 | 550 | 0.170 |
Why?
|
| Truth Disclosure | 1 | 2000 | 93 | 0.170 |
Why?
|
| Internal Medicine | 2 | 2014 | 362 | 0.170 |
Why?
|
| Attitude | 1 | 2000 | 130 | 0.170 |
Why?
|
| Attitude to Health | 1 | 2021 | 222 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2014 | 666 | 0.160 |
Why?
|
| Workload | 1 | 2020 | 129 | 0.160 |
Why?
|
| Mobility Limitation | 1 | 2019 | 19 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2023 | 9216 | 0.160 |
Why?
|
| Pharmacogenetics | 1 | 2022 | 437 | 0.160 |
Why?
|
| Medicaid | 1 | 2022 | 242 | 0.160 |
Why?
|
| Splenic Vein | 1 | 2018 | 5 | 0.160 |
Why?
|
| Gastric Fundus | 1 | 2018 | 7 | 0.160 |
Why?
|
| Risk Adjustment | 1 | 2018 | 38 | 0.160 |
Why?
|
| Mesenteric Veins | 1 | 2018 | 34 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1243 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 784 | 0.150 |
Why?
|
| Ethics, Medical | 1 | 2000 | 306 | 0.150 |
Why?
|
| Prognosis | 3 | 2016 | 3800 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 983 | 0.140 |
Why?
|
| Steroids | 1 | 2018 | 173 | 0.140 |
Why?
|
| Health Services | 1 | 2017 | 57 | 0.140 |
Why?
|
| Negotiating | 1 | 2016 | 20 | 0.140 |
Why?
|
| Transitional Care | 1 | 2016 | 18 | 0.130 |
Why?
|
| Medication Reconciliation | 1 | 2016 | 6 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1691 | 0.130 |
Why?
|
| Home Care Services | 1 | 2017 | 77 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2016 | 2886 | 0.130 |
Why?
|
| Managed Care Programs | 1 | 1996 | 42 | 0.130 |
Why?
|
| Employment | 1 | 1996 | 53 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 654 | 0.120 |
Why?
|
| Career Choice | 1 | 1997 | 148 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 69 | 0.120 |
Why?
|
| Medical Records | 1 | 2015 | 120 | 0.120 |
Why?
|
| Research Design | 1 | 2018 | 591 | 0.120 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2588 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 327 | 0.120 |
Why?
|
| Cell Hypoxia | 2 | 2016 | 173 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 2014 | 29 | 0.120 |
Why?
|
| Patient Handoff | 1 | 2016 | 95 | 0.120 |
Why?
|
| Empathy | 1 | 2016 | 151 | 0.120 |
Why?
|
| Cost Control | 1 | 2014 | 45 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 2657 | 0.120 |
Why?
|
| Health Services Research | 1 | 2014 | 138 | 0.110 |
Why?
|
| Trust | 1 | 2013 | 97 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2015 | 1497 | 0.100 |
Why?
|
| Massachusetts | 1 | 2011 | 33 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2018 | 4329 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2015 | 387 | 0.100 |
Why?
|
| Students, Medical | 1 | 1997 | 425 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1169 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 1 | 2011 | 28 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2017 | 8277 | 0.090 |
Why?
|
| Insurance Claim Review | 1 | 2011 | 45 | 0.090 |
Why?
|
| Streptococcus pneumoniae | 1 | 2011 | 49 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 797 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2011 | 171 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 199 | 0.090 |
Why?
|
| Outpatients | 1 | 2011 | 101 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 91 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2014 | 457 | 0.090 |
Why?
|
| Mortality | 1 | 2011 | 149 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2011 | 171 | 0.080 |
Why?
|
| Time Factors | 2 | 2018 | 5358 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 848 | 0.080 |
Why?
|
| Adolescent | 3 | 2016 | 9345 | 0.070 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2017 | 20 | 0.070 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 59 | 0.070 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 69 | 0.070 |
Why?
|
| Incidence | 1 | 2011 | 1604 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 142 | 0.070 |
Why?
|
| Specialization | 2 | 1997 | 70 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 198 | 0.060 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2015 | 40 | 0.060 |
Why?
|
| Neoplasms | 1 | 2000 | 3067 | 0.060 |
Why?
|
| Consensus | 1 | 2017 | 366 | 0.060 |
Why?
|
| Young Adult | 2 | 2016 | 6415 | 0.060 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 8 | 0.060 |
Why?
|
| Cell Survival | 1 | 2016 | 983 | 0.060 |
Why?
|
| Response Elements | 1 | 2014 | 69 | 0.060 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 86 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2016 | 372 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 1 | 2014 | 69 | 0.060 |
Why?
|
| Quality Control | 1 | 2014 | 117 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2014 | 278 | 0.050 |
Why?
|
| Cytosine | 1 | 2014 | 130 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 135 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 301 | 0.050 |
Why?
|
| 5-Methylcytosine | 1 | 2014 | 117 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 156 | 0.050 |
Why?
|
| Child | 2 | 2015 | 7242 | 0.050 |
Why?
|
| Cell Movement | 1 | 2016 | 787 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 283 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 33 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1801 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1731 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 495 | 0.050 |
Why?
|
| Pharmacogenomic Testing | 1 | 2022 | 95 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 557 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2014 | 726 | 0.050 |
Why?
|
| Heart Failure | 1 | 2011 | 1253 | 0.050 |
Why?
|
| Cross-Cultural Comparison | 1 | 2000 | 34 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1670 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 606 | 0.040 |
Why?
|
| Japan | 1 | 2000 | 304 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 521 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 1066 | 0.040 |
Why?
|
| Models, Biological | 1 | 2016 | 1766 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2000 | 230 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1533 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2020 | 234 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 2000 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1284 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2022 | 413 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2018 | 67 | 0.040 |
Why?
|
| Phenotype | 1 | 2014 | 2457 | 0.040 |
Why?
|
| Infant | 1 | 2014 | 3189 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2014 | 1380 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 225 | 0.030 |
Why?
|
| General Practice | 1 | 2016 | 9 | 0.030 |
Why?
|
| Medicine | 1 | 1997 | 91 | 0.030 |
Why?
|
| California | 1 | 1996 | 146 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2415 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2360 | 0.030 |
Why?
|
| Forecasting | 1 | 1996 | 304 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 166 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 216 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 179 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1055 | 0.030 |
Why?
|
| Patient Admission | 1 | 2013 | 114 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2013 | 196 | 0.030 |
Why?
|
| Education, Medical | 1 | 1996 | 243 | 0.030 |
Why?
|
| Mice | 1 | 2016 | 11858 | 0.030 |
Why?
|
| Health Surveys | 1 | 2013 | 240 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2018 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1913 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 27536 | 0.020 |
Why?
|
| Hyperthermia, Induced | 2 | 1956 | 73 | 0.010 |
Why?
|
| Rhinitis, Allergic, Seasonal | 2 | 1956 | 179 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1953 | 71 | 0.010 |
Why?
|
| Agglutinins | 1 | 1950 | 4 | 0.010 |
Why?
|
| Typhoid Fever | 1 | 1950 | 4 | 0.010 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 1950 | 5 | 0.010 |
Why?
|
| Agglutination | 1 | 1950 | 17 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1950 | 43 | 0.010 |
Why?
|